US EditionPublished • loading... • Updated
Bank of America hikes Eli Lilly price target on promising drug pipeline
Summary by Pop News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Bank of America hikes Eli Lilly price target on promising drug pipeline
Bank of America is standing by its bullish outlook on Eli Lilly . The bank reiterated its buy rating on the pharmaceutical stock. It also hiked its price target to $1,286 from $950, which points to 22% upside. Analyst Tim Anderson applauded Eli Lilly for maintaining its “first place” status in the large obesity and diabetes market with its GLP-1 drugs, Zepbound and Mounjaro. LLY YTD mountain LLY YTD chart “While the obesity category is complex, …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
